Delphi advisor to Pareto Securities in connection with rights issue

Delphi has assisted Pareto Securities AB in connection with a rights issue of units of approximately SEK 343 million in Xbrane Biopharma AB (publ). Xbrane Biopharma AB’s share is listed on Nasdaq Stockholm.

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems.

Delphi’s team consisted of Mats Dahlberg, Jenny Lindén and Tove Rodlert.